RGNX vs. INDV, AMPH, ARDX, EVO, ETNB, OCUL, GPCR, IOVA, CALT, and AUPH
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), Iovance Biotherapeutics (IOVA), Calliditas Therapeutics AB (publ) (CALT), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry.
REGENXBIO vs.
REGENXBIO (NASDAQ:RGNX) and Indivior (NASDAQ:INDV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking.
REGENXBIO currently has a consensus target price of $33.88, suggesting a potential upside of 312.61%. Indivior has a consensus target price of $15.00, suggesting a potential upside of 56.58%. Given REGENXBIO's higher possible upside, research analysts plainly believe REGENXBIO is more favorable than Indivior.
Indivior has a net margin of -3.96% compared to REGENXBIO's net margin of -283.19%. REGENXBIO's return on equity of -70.65% beat Indivior's return on equity.
REGENXBIO received 432 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 65.63% of users gave REGENXBIO an outperform vote.
In the previous week, REGENXBIO had 14 more articles in the media than Indivior. MarketBeat recorded 16 mentions for REGENXBIO and 2 mentions for Indivior. Indivior's average media sentiment score of 1.88 beat REGENXBIO's score of 0.52 indicating that Indivior is being referred to more favorably in the news media.
Indivior has higher revenue and earnings than REGENXBIO. Indivior is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 13.1% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
REGENXBIO has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
Summary
REGENXBIO beats Indivior on 10 of the 19 factors compared between the two stocks.
Get REGENXBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
REGENXBIO Competitors List
Related Companies and Tools
This page (NASDAQ:RGNX) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy RGNX Stock Free RGNX Stock Alerts